Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Key result
Sacubitril-valsartan fails to reduce HF hospitalizations and CV death versus valsartan in HFpEF.
- RR 0.87
- P=0.06
Why the study?
Does sacubitril-valsartan reduce total hospitalizations for heart failure and death from cardiovascular causes in patients with heart failure and an ejection fraction of 45% or higher?
Population
Patients with heart failure and an ejection fraction of 45% or higher
Authors
Discussion
Loading...
Member takes
Implication
Clinicians should not routinely prescribe sacubitril-valsartan for HFpEF; challenges consensus extrapolation from HFrEF benefits.
Structured PICO
Does sacubitril-valsartan reduce total hospitalizations for heart failure and death from cardiovascular causes in patients with heart failure and an ejection fraction of 45% or higher?
P
Population
patients with heart failure and an ejection fraction of 45% or higher
I
Intervention
Sacubitril-valsartan
O
Outcome
total hospitalizations for heart failure and death from cardiovascular causescomposite
Sacubitril-valsartan did not significantly reduce the composite of heart failure hospitalizations and cardiovascular death in patients with HFpEF (LVEF ≥45%).
Cite This Study
Solomon et al. (2019) studied this question. Sacubitril-valsartan did not significantly reduce the rate of heart failure hospitalizations and cardiovascular death (RR 0.87, P=0.06) versus valsartan in patients with HFpEF.